Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part I: the effect of size.
Nanomedicine (Lond)
; 15(20): 1927-1945, 2020 08.
Article
en En
| MEDLINE
| ID: mdl-32820673
ABSTRACT
Background:
Lymphangioleiomyomatosis (LAM) is characterized by growth of smooth muscle-like cells in the lungs that spread to other organs via lymphatic vessels. Current oral rapamycin treatment is limited by low bioavailability of approximately 15%.Aim:
The effect of inhaled rapamycin solid lipid nanoparticles (Rapa-SLNs) size on its penetration through the lymphatics.Method:
Three Rapa-SLN formulations (200-1000 nm) were produced and assessed for particle characteristics and further for toxicity and performance in vitro.Results:
Rapa-SLNs of 200 nm inhibited proliferation in TSC2-negative mouse embryonic fibroblast cells and penetrated the respiratory epithelium and lymphatic endothelium significantly faster compared with free rapamycin and larger Rapa-SLNs.Conclusion:
Rapa-SLN approximately 200 nm allows efficient entry of rapamycin into the lymphatic system and is therefore a promising treatment for LAM patients.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Vasos Linfáticos
/
Nanopartículas
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Nanomedicine (Lond)
Año:
2020
Tipo del documento:
Article
País de afiliación:
Australia